Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The THRIVE program by ARPA-H seeks innovative solutions for treating hereditary rare diseases through in vivo precision genetic medicines. Interested parties should submit solution summaries by October 31, 2025. For more details, visit the ARPA-H website.
The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.
Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122.
For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131.
Solution summaries are due October 31, 2025, 11:59 PM ET.
For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive
TREATING HEREDITARY RARE DISEASES WITH IN VIVO PRECISION GENETIC MEDICINES (THRIVE) is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.